Education
About Us
Working with TipRanks
Follow Us
Peptidream Inc. (PPTDF)
OTHER OTC:PPTDF
PPTDF Stock Chart & Stats
$11.75
$0.00(0.00%)
At close: 4:00 PM EST
$11.75
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$8.57 - $15.83
Previous CloseN/A
Volume10.00
Average Volume (3M)53.00
Market Cap
$1.18B
Enterprise Value$173.20B
Total Cash (Recent Filing)$28.68B
Total Debt (Recent Filing)$17.04B
Price to Earnings (P/E)―
Beta0.42
Next Earnings
May 19, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding130,010,400
10 Day Avg. Volume0
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market Cap146.68
Enterprise Value/Revenue9.35
Enterprise Value/Gross Profit23.02
Enterprise Value/Ebitda-65.50
Forecast
1Y Price Target
$20.75Price Target Upside76.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.85
Revenue Forecast (FY)$331.32M
Bulls Say, Bears Say
Bulls Say
Proprietary PDPS Platform & Scientific EdgePeptiDream's proprietary peptide discovery platform and recent scientific demonstrations (extrahepatic delivery, in vivo proof-of-concept immune engagers) create durable technical differentiation. This increases partner interest, supports recurring collaborations and strengthens long-term deal flow and platform monetization.
Expanding Clinical PipelineRapid pipeline progression to 13 clinical programs and a target of 19–25 by end-2026 evidences scalable discovery-to-development capabilities. More clinical programs increases milestone and royalty optionality and diversifies payoff drivers across modalities and indications over the medium term.
Strong Cash Position And Balance-sheet ResilienceA JPY 28.6B cash balance and net-cash status provide multi-quarter runway to fund R&D and planned manufacturing expansion without immediate equity raises. The improving equity ratio and stated no-planned-equity-financing stance support financial flexibility while the company executes on pipeline and capex plans.
Bears Say
2025 Profit Swing & Cash-flow DeteriorationThe 2025 reversal from prior profitability to sizeable operating and free cash flow losses is a durable concern: sustained cash burn reduces margin for execution risk, limits discretionary investment, and raises reliance on milestone/upfront receipts or asset monetization to restore long-term financial stability.
Revenue Timing Risk From Delayed Out‑licensingDependence on large, timing‑sensitive upfront/out‑licensing deals creates structural revenue volatility. Delays (myostatin and other programs) push milestone receipts out, magnify cash-burn sensitivity, and reduce near-term visibility for funding capex and R&D without altering longer-term program value.
Rising R&D And Headcount-driven Cost PressureA structurally higher R&D budget and rising headcount (preparing radiopharma launches) raise fixed operating burn. If milestone timing slips, higher recurring costs accelerate cash depletion, constrain strategic optionality and extend the timeframe before internal programs can generate self‑funding revenue.
Peptidream News
PPTDF FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was $8.57 and its highest was $15.83 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is $1.18B.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is May 19, 2026 which is in 77 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on Feb 16, 2026. The company reported -$0.026 earnings per share for the quarter, beating the consensus estimate of -$0.036 by $0.01.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -0.03.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -$0.026 in its last earnings report, beating expectations of -$0.036. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in PPTDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
PPTDF Company Deck
PPTDF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.View all PPTDF earnings summariesPPTDF Stock 12 Month Forecast
Average Price Target
$20.75
▲(76.59% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.65% Mutual Funds
― Other Institutional Investors
93.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---